Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 avr. 2025 10h05 HE | Source: Spherix Global Insights

Johnson & Johnson’s Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights

EXTON, PA, April 14, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson’s recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable...
13 févr. 2025 11h55 HE | Source: Spherix Global Insights

Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market

EXTON, PA, Feb. 13, 2025 (GLOBE NEWSWIRE) -- UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic arthritis (PsA) market, with early indicators suggesting it could drive a...
01 mai 2024 06h55 HE | Source: Janssen Cilag International NV

Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease

Media contact:Sophie DaneauSdaneau@its.jnj.com+33 6 3178 8798Investor contact:Raychel Kruperinvestor-relations@its.jnj.com For European and UK medical and trade media only For immediate...